Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AM-101 in Post-Acute Peripheral Tinnitus (AMPACT1)
NCT01934010Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Jun 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gacyclidine in tinnitus, sponsored by Altamira Therapeutics. Started Jun 2014; status: completed.
02
Drugs
gacyclidine
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT01934010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01934010.